The Results of a 12-Month Open-Label Follow-Up Study with MRI Monitoring of Patients with Parkinson’s Disease After MRI-Guided FUS

<b>Background:</b> Tremor-dominant Parkinson's disease (TDPD) is the most common subtype of PD. Tremor is difficult to treat and less than 50% of patients respond to dopaminergic medications. Magnetic resonance guided focused ultrasound (MRgFUS) thalamotomy is an incisionless noninvasive method for treating pharmacoresistant tremor in PD patients, but its effect on progression of PD is unknown. In this study, we investigate the efficacy of MRgFUS thalamotomy on progression of motor and non-motor symptoms, using a levodopa equivalent daily dose (LEDD) requirement. <b>Methods:</b> A total of 21 PD patients with ineffective tremor correction by medical therapy underwent MRgFUS thalamotomy. Assessments of motor and non-motor symptoms, adverse events (AE), changes in LEDD, and evolution of FUS (focused ultrasound) lesion were performed on the day before surgery, and then 2 days, as well as 3, 6, and 12 months, after the procedure. <b>Results:</b> On the 2nd day after FUS thalamotomy, 11 patients were tremor-free and, in 10 patients, tremor decreased by 80-90% with a concomitant reduction in hypokinesia and rigidity. By the end of the 12th month, 5 patients remained tremor-free; in 11 patients, mild/moderate tremor re-emerged; and in 5 patients, there was a relapse of severe tremor. Quality of life (QoL) and activities of daily living (ADL) improved significantly at 3 months and remained stable thereafter. Cognitive function improved in patients with baseline MoCA score < 26 points at 3 months after FUS. Anxiety progressed between baseline and end of follow-up. By the end of the follow-up period, LEDD was lowered or stable in 9 patients. Four patients had persistent mild AE. <b>Conclusions:</b> This open label study suggests a beneficial effect of MRgFUS in reducing tremor, hypokinesia, and rigidity and improving QoL, ADL, and cognitive function in TDPD patients in the short term, although long-term data needs to be collected in further studies.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-11-24
DOI
https://doi.org/10.3390/jcm14238329
Citations
1
Primary Topic
Neurological disorders and treatments
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Results of a 12-Month Open-Label Follow-Up Study with MRI Monitoring of Patients with Parkinson’s Disease After MRI-Guided FUS

Nataliya Titova, Mikhail Dolgushin, R. T. Tairova, V M Dzhafarov et al.
1 citations
Journal of Clinical Medicine
Neurological disorders and treatments
1.39
article

The Results of a 12-Month Open-Label Follow-Up Study with MRI Monitoring of Patients with Parkinson’s Disease After MRI-Guided FUS

Nataliya Titova, Mikhail Dolgushin, R. T. Tairova, V M Dzhafarov, I. V. Senko, Ivan S. Gumin, Е А Катунина, Vsevolod Vadimovich Belousov, N N Shipilova, M. Yu. Martynov, M.Z. Ivanova Ivanova
article en
1 citations

Abstract

<b>Background:</b> Tremor-dominant Parkinson's disease (TDPD) is the most common subtype of PD. Tremor is difficult to treat and less than 50% of patients respond to dopaminergic medications. Magnetic resonance guided focused ultrasound (MRgFUS) thalamotomy is an incisionless noninvasive method for treating pharmacoresistant tremor in PD patients, but its effect on progression of PD is unknown. In this study, we investigate the efficacy of MRgFUS thalamotomy on progression of motor and non-motor symptoms, using a levodopa equivalent daily dose (LEDD) requirement. <b>Methods:</b> A total of 21 PD patients with ineffective tremor correction by medical therapy underwent MRgFUS thalamotomy. Assessments of motor and non-motor symptoms, adverse events (AE), changes in LEDD, and evolution of FUS (focused ultrasound) lesion were performed on the day before surgery, and then 2 days, as well as 3, 6, and 12 months, after the procedure. <b>Results:</b> On the 2nd day after FUS thalamotomy, 11 patients were tremor-free and, in 10 patients, tremor decreased by 80-90% with a concomitant reduction in hypokinesia and rigidity. By the end of the 12th month, 5 patients remained tremor-free; in 11 patients, mild/moderate tremor re-emerged; and in 5 patients, there was a relapse of severe tremor. Quality of life (QoL) and activities of daily living (ADL) improved significantly at 3 months and remained stable thereafter. Cognitive function improved in patients with baseline MoCA score < 26 points at 3 months after FUS. Anxiety progressed between baseline and end of follow-up. By the end of the follow-up period, LEDD was lowered or stable in 9 patients. Four patients had persistent mild AE. <b>Conclusions:</b> This open label study suggests a beneficial effect of MRgFUS in reducing tremor, hypokinesia, and rigidity and improving QoL, ADL, and cognitive function in TDPD patients in the short term, although long-term data needs to be collected in further studies.

Journal of Clinical MedicineVol. 14(23)
Pirogov Russian National Research Medical University (RU), Federal Medical-Biological Agency (RU)
Openalex Percentile: Top 14%
Neurological disorders and treatments
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.